Ceptaris Therapeutics has obtained FDA marketing approval for Valchlor (mechlorethamine) gel to topically treat stage IA and IB mycosis fungoides-type cutaneous T-Cell lymphoma (CTCL) patients who were exposed to skin-directed therapy ...
Tags: Valchlor Gel, Ceptaris